Afatinib for patients with non-small-cell lung cancer harboring major EGFR G719X + S768I co-mutations: a retrospective, observation study in Xuanwei and Fuyuan, China
Chinese Clinical Oncology · 2025
DOI: 10.21037/cco-25-43 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Chinese Clinical Oncology, 2025. Verfasst von Ruoyu Deng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Qujing First People's Hospital/Kunming Medical University Affiliated Qujing Hospital, Qujing, China. Hauptthemen laut MEDLINE: Afatinib, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Qujing First People's Hospital/Kunming Medical University Affiliated Qujing Hospital, Qujing, China.
Zitieren
APA
Deng, R., Wang, L., Lv, J., Liu, F., Zhang, T., Li, C., Li, C., Zhang, Z., Zhou, H., Zhang, W., & Zhang, C. (2025). Afatinib for patients with non-small-cell lung cancer harboring major EGFR G719X + S768I co-mutations: a retrospective, observation study in Xuanwei and Fuyuan, China. Chinese Clinical Oncology. https://doi.org/10.21037/cco-25-43
Vancouver
Deng R, Wang L, Lv J, Liu F, Zhang T, Li C, et al. Afatinib for patients with non-small-cell lung cancer harboring major EGFR G719X + S768I co-mutations: a retrospective, observation study in Xuanwei and Fuyuan, China. Chinese Clinical Oncology. 2025. doi:10.21037/cco-25-43
BibTeX
@article{Deng2025,
author = {Deng, Ruoyu and Wang, Lin and Lv, Jialing and Liu, Feineng and Zhang, Tengfei and Li, Chunyan and Li, Chongxin and Zhang, Zhijun and Zhou, Huahua and Zhang, Wen and Zhang, Chao},
title = {Afatinib for patients with non-small-cell lung cancer harboring major EGFR G719X + S768I co-mutations: a retrospective, observation study in Xuanwei and Fuyuan, China},
journal = {Chinese Clinical Oncology},
year = {2025},
doi = {10.21037/cco-25-43}
}
EUVIMED